- Home
- ESLA vs UG Comparison
ESLA vs UG Comparison
Compare ESLA & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- UG
- Stock Information
- Founded
- ESLA 2021
- UG 1942
- Country
- ESLA United States
- UG United States
- Employees
- ESLA N/A
- UG N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- UG Package Goods/Cosmetics
- Sector
- ESLA Health Care
- UG Consumer Discretionary
- Exchange
- ESLA Nasdaq
- UG Nasdaq
- Market Cap
- ESLA 35.5M
- UG 37.9M
- IPO Year
- ESLA N/A
- UG N/A
- Fundamental
- Price
- ESLA $0.85
- UG $8.01
- Analyst Decision
- ESLA Strong Buy
- UG
- Analyst Count
- ESLA 1
- UG 0
- Target Price
- ESLA $16.00
- UG N/A
- AVG Volume (30 Days)
- ESLA 18.1K
- UG 12.9K
- Earning Date
- ESLA 08-20-2025
- UG 08-12-2025
- Dividend Yield
- ESLA N/A
- UG 8.74%
- EPS Growth
- ESLA N/A
- UG 4.93
- EPS
- ESLA N/A
- UG 0.63
- Revenue
- ESLA N/A
- UG $11,408,154.00
- Revenue This Year
- ESLA N/A
- UG N/A
- Revenue Next Year
- ESLA N/A
- UG N/A
- P/E Ratio
- ESLA N/A
- UG $12.75
- Revenue Growth
- ESLA N/A
- UG N/A
- 52 Week Low
- ESLA $0.63
- UG $7.73
- 52 Week High
- ESLA $1.81
- UG $16.25
- Technical
- Relative Strength Index (RSI)
- ESLA 45.00
- UG 41.12
- Support Level
- ESLA $0.82
- UG $7.80
- Resistance Level
- ESLA $0.95
- UG $9.78
- Average True Range (ATR)
- ESLA 0.07
- UG 0.49
- MACD
- ESLA 0.00
- UG -0.15
- Stochastic Oscillator
- ESLA 44.06
- UG 10.10
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About UG United-Guardian Inc.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.